Thailand Prepares 6 Million Shots For Mass Rollout’s First Month
(Bloomberg) -- Thailand aims to administer as many as 6 million shots to protect against Covid-19 this month, as it begins a mass vaccination program amid the nation's worst coronavirus outbreak since the pandemic began.
The government plans to distribute about 2 million doses of AstraZeneca Plc and Sinovac Biotech Ltd. to vaccination sites across Thailand ahead of the June 7 rollout, according to Sopon Iamsirithawon, a deputy director-general at the Department of Disease Control. As many as 6 million shots will be available in June, with a target capacity of about 500,000 inoculations a day, he said.
The Southeast Asian nation's economy may not return to pre-pandemic growth levels until early 2023, three fiscal quarters later than previously expected, the Bank of Thailand warned Monday. A surge in coronavirus cases since early April has seen deaths from infections soar more than tenfold and triggered restrictions across the country. The government yesterday approved an additional $4.5 billion of stimulus to counter the economic and social impacts.
“Thailand is currently in the same situation as most countries in the world: many people to vaccinate and limited vaccines with which to do it,” said Daniel Kertesz, the World Health Organization's representative to Thailand. “The ultimate goal would be to vaccinate everyone who's eligible, but it's not possible in the short term so the really important lesson is that prioritizing will be key to success.”
A target of administering 100 million shots to cover about 70% of the population by the end of the year compares with coverage of less than than 3% in the past three months. The distribution of millions of shots each month from June will allow expansion of the inoculation program to prioritize residents of Bangkok, the epicenter of the surge in cases.
READ: Majority of Thais Unhappy With Government's Handling of Covid
| Manufacturers | Government Orders | Delivery |
|---|---|---|
| AstraZeneca Plc | 61 million doses | From June; multiple lots |
| Sinovac Biotech Ltd. | 10-15 million doses | From Feb.; multiple lots |
| Pfizer Inc. | 20 million doses (in talks) | Before Sept. |
| Johnson & Johnson | 5 million doses (in talks) | Before Sept. |
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.